Updated:
Tuesday,
18 mayo, 2021
12:53
Published:
18.05.2021 12:10
–
–
–
People with a first dose of AstraZeneca Those who received a second Pfizer increased their immune response against COVID without increasing the known side effects, the vast majority mild and moderate. This was announced in the presentation of the CombivacS study promoted by the Carlos III Health Institute. These are preliminary results that confirm that mixing both brands is safe and effective.
According to Jesús Antonio Frías, coordinator of the clinical research network of the Carlos III Health Institute, “Those who have received a first dose of AstraZeneca can safely and effectively receive a second dose of Comirnaty (Pfizer)”.
Frías explained in the presentation of the study that “we as research scientists can only conclude that the administration of a booster dose through a heterologous vaccination scheme is highly immunogenic, the increase in antibodies between 30 and 40 times from seven to fourteen days, and the adverse reactions are similar to those seen in single administration regimens in other programs, in no case serious or have they led to hospital admissions. “
Between the adverse effects, highlighting that pain at the injection site it is the most frequent symptom (88%). Between 30-35% of people who received the second dose of Pfizer also they had erythema or induration at the site and other “less frequent” symptoms were itching at the injection site. “If we analyze the systemic reactogenicity data, the most frequent are general malaise and headache (more than 40%), also 25% manifested chills, although only 2.5% of the participants said they had had a fever “, explains Dr. Magdalena Campins, head of the Preventive Medicine service at the Vall d’Hebron Hospital.
These are preliminary results of the CombiVacs study on the combination of AstraZeneca and Pfizer vaccines, which will allow a decision on the second dose in people under 60 years of age who received the first dose of AstraZeneca.
In this essay 676 patients of different age groups participated and regions of Spain that have received a single dose of AstraZeneca and range from 18 to 59 years. They have been divided into two groups: one of 226 who received the dose “immediately” and another of 450 who received it after 28 days. The results presented today are those analyzed 14 days after receiving the Pfizer dose.
And precisely today the Public Health Commission meets To decide how you will immunize these people, who should start completing their regimen next week. On April 30, they agreed to extend the interval between doses for this group to 16 weeks -not so for those over 60-, although it is recommended by the European Medicines Agency is that the 12-week guideline is respected, which is also the one contemplated in the drug’s own leaflet.
The Commission then preferred to collect more scientific evidence to guarantee the safety of vaccination with Anglo-Swedish serum in this age group, in which its use was discouraged as its link to very rare cases of thrombi associated with thrombocytopenia was confirmed. Now these CombiVacs findings will be considered alongside other factors.
–
